The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for ravulizumab (Alexion Pharmaceuticals Australasia Pty Ltd)
Active ingredients
ravulizumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Injection, intravenous infusion
Indication
For the treatment of paroxysmal nocturnal haemoglobinuria (PNH)
Therapeutic area
Haematology